ISCD Learning
February 2024 - Quality Bone Densitometry: Performance, Interpretation, and Clinical Application for Clinicians
Includes a Live In-Person Event on 05/07/2024 at 12:00 AM (EDT)
- Registration Closed
Course Date
February 3 & 4, 2024.
Course Description
The core elements of this course serve to educate healthcare providers about bone densitometry and osteoporosis and to apply standard practices to assure quality performance and interpretation of bone densitometry studies. The course is offered in two parts. The first day sets the standard to perform Quality DXA interpretation. Day 2 focuses on the clinical assessment, prevention, treatment and management of osteoporosis and the essential role that high-quality DXA plays in treatment initiation decisions and monitoring of osteoporotic patients. Individuals may register for either part of the course separately or as a combined program.
Target Audience
The course is most appropriate for those involved in the performance and interpretation of DXA scans and those managing patients with osteoporosis. It is open to MDs, PhDs, DOs, Nurse Practitioners, and Physician Assistants. Technologists may attend if they have previously taken the ISCD/IOF Osteoporosis Essentials for Technologists Course.
Learning Objectives
After attending the course, participants should be better prepared to:
- Describe appropriate clinical evaluation of patients at risk for fragility fracture.
- Summarize the value and importance of quality bone densitometry for the diagnosis of osteoporosis, assessment of fracture risk, and monitoring of BMD.
- Recognize errors in DXA analysis and reporting.
- Explain new and emerging guidelines that provide evidence-based information regarding skeletal health.
- Describe the use of current and new pharmacologic therapies for the management and treatment of osteoporosis, including adverse effects.
Method of Participation
This activity will be offered live streamed via Zoom, allowing the learner to watch and ask questions in a live format on February 3 & 4, 2024. Learners will be asked to complete a post-course survey to indicate what they will change in their practice as a result of this activity.
Rates
Cancellation Policy
Attendee Cancellation Policy All changes in registration must be made in writing to education@iscd.org. Cancellations received 30 days prior to the start of the program are eligible for a full refund minus a $50 administrative fee. Cancellations received less than 30 days prior to the start of the course will not be refunded.
Course Changes or Cancellations ISCD reserves the right to cancel the program, change dates and/or meeting location. If a program is canceled, all program fees will be refunded automatically unless the registered participant elects to transfer to another program. Participants will be notified of any changes within 21 days of the course start date.
Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISCD. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation Provider Number: 4008163
AMA PRA Category 1 Credit(s)™
Amedco LLC designates this live activity for a maximum of 13.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Deadline to Claim Credit:
Participants will have 90 days from the activity end date to complete the activity survey and claim continuing education credit.
Schedule - February 3rd, 2024 - All times Eastern Standard Time (NYC/USA)
Schedule - February 4th, 2024 - All times Eastern Standard Time (NYC/USA)
S. Bobo Tanner, MD, CCD
Director of the Vanderbilt Osteoporosis Clinic
Vanderbilt University Medical Center
S. Bobo Tanner, MD, CCD, is a graduate of Harvard University in Cambridge, Massachusetts, with a BA in History and Science, and received his medical degree with honors from Bowman Gray Medical School of Wake Forest University, Winston-Salem, North Carolina. He pursued his internship and residency at the Vanderbilt University Hospital in Nashville, Tennessee, and completed fellowships and board certification in Rheumatology and in Allergy/Immunology. Dr. Tanner served as a Registrar in the Department of Rheumatology at the Royal Free Hospital, London, England.
Afterwards he returned to Vanderbilt and was Founder and Director of the Vanderbilt Osteoporosis Clinic which is part of the Rheumatology Division.
In 2007 he received the Clinician of the Year Award from International Society for Clinical Densitometry and in 2017 he was recognized with the President’s Award from the Tennessee Rheumatology Society.
His professional membership and service includes the American College of Physicians, Fellow of the American College of Rheumatology, member of the Royal Society of Medicine, and the American Academy of Asthma, Allergy & Immunology, past secretary/ treasurer of the Tennessee Rheumatology Society, past president of the Tennessee Allergy Society and past president of the International Society for Clinical Densitometry. He currently works on the ISCD Education Council where he updates and teaches the CME Bone Density Courses throughout the year. He is a Certified Clinical Densitometrist. His is on the editorial board for the Journal of Clinical Densitometry and Therapeutic Advances in Musculoskeletal Disease.
Ginnie Prater, MD, CCD
Medical Director
Blue Cross and Blue Shield of Alabama
Dr. Ginnie Prater is a medical director at Blue Cross and Blue Shield of Alabama. Her primary area of responsibility is utilization management. She also works with the Health Equity and Medicare Advantage teams. Dr. Prater graduated from Indiana State University with a BS in Chemistry in 1999. She completed medical training at the University of Alabama School of Medicine. She maintains board certifications in Internal Medicine and Geriatric Medicine. Dr. Prater is a certified clinical densitometrist and a certified medical director. Prior to her work at Blue Cross and Blue Shield of Alabama, Dr. Prater was a full-time academic geriatrician and clinician-educator. She continues to practice part-time at UAB in the Osteoporosis Prevention and Treatment clinic. She continues to work with the International Society of Clinical Densitometry (ISCD) on the education committee, with a goal of enhancing the quality of musculoskeletal health assessments and treatments.
Gillian Wooldridge, DO, CCD
Gillian Wooldridge is a primary care sports medicine physician in Houston, Texas. She completed her undergraduate studies in Kinesiology-Sports Medicine at Rice University in 2009. She received her medical degree from the Texas College of Osteopathic Medicine in 2014, where she was the inaugural recipient of the Sports Medicine Achievement Award. Dr Wooldridge completed her family medicine residency in 2017 and sports medicine fellowship in 2018, with Houston Methodist and Houston Methodist Willowbrook Hospitals respectively.
She currently works for Houston Methodist Orthopedics and Sports Medicine in the Texas Medical Center. She serves as a team physician for Rice University Athletics and volunteers with several organizations in the community including the Chevron Houston Marathon, IronMan Texas and the Houston Livestock Show and Rodeo. Dr Wooldridge is a member of the board of directors for the American Osteopathic Academy of Sports Medicine and is actively involved in the American Medical Society of Sports Medicine as an item writer for the sports medicine in-training exam.
She is a certified clinical densitometrist and works on the Osteoporosis Essentials Course Committee and serves as a co-director of the Bone Health Initiative in the Houston Methodist Orthopedics and Sports Medicine department. She holds a core clinical faculty position with the Texas A&M College of Medicine Engineering & Medicine program and a clinical faculty position the Tillman Fertitta Family College of Medicine.
Steven M. Petak, MD, JD, MACE, FACP
Division Head and Clinical Service Chief Endocrinology
Houston Methodist Hospital
Dr. Steven Petak is a clinical and academic endocrinologist in Houston, Texas.
He is a past president of the American Association of Clinical Endocrinologists, the American College of Endocrinology (www.aace.com), and the International Society for Clinical Densitometry (www.iscd.org). He is an associate clinical professor at Weill-Cornell Medical College at the Houston Methodist Hospital and is the division head of endocrinology, diabetes and metabolism as well as service chief of endocrinology. He is a bone densitometry and endocrine consultant to NASA at the Johnson Space Center for about 13 years and has been a part of the bone summit planning long duration space missions. He is the secretary of the board of councilors of the Texas Medical Association (2015) and represents the Harris County Medical Society as vice-councilor.
His awards include Master of the American College of Endocrinology, Yank Coble Public Service Award of the American College of Endocrinology, the ISCD Paul Miller Public Service Award, and ISCD Clinician of the Year. He has authored and co-authored articles, editorials and guidelines in endocrinology and reproductive medicine.
He received his MD from the University of Illinois in Chicago and has his JD from the University of Houston (Magna cum Laude). He had his internship, residency, medical chief residency, and fellowship in endocrinology and metabolism at the University of Texas at Houston. He was at the Texas Institute for Reproductive Medicine and Endocrinology in Houston for about 26 years before joining the academic endocrine group at Methodist in May 2013. He is board certified in internal medicine as well as endocrinology and metabolism.
Statement of Independence
The ISCD maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the ISCD provide in-depth presentations that are fair, balanced, independent, and scientifically rigorous. ISCD requires faculty, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ISCD for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Individual disclosures are included in the course material. No Commercial Support has been provided for this activity
Disclaimer
The information and suggestions presented at the courses, seminars and other programs sponsored by ISCD and other collaborating societies are subject to change and therefore should serve only as a foundation for further investigation and study. Any forms presented at our seminars or programs are samples only and are not necessarily authoritative. All information, procedures, and forms contained or used in such seminars or programs should serve only as a guide for use in specific situations.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. ISCD does not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for a discussion of approved indications, contraindications, and warnings.
Privacy & Confidentiality Statement
The ISCD will record the learner’s personal information as provided on evaluations to allow for the issuance and tracking of CME/CE certificates. The ISCD may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its educational program. No individual performance data or any other personal information collected for evaluations will be shared with third parties
Attendance Cancellation Policy
All changes in registration must be made in writing to education@iscd.org. Cancellations received 30 days prior to the start of the program are eligible for a full refund minus a $50 administrative fee. Cancellations received less than 30 days prior to the start of the course will not be refunded.
Course Changes or Cancellations
ISCD reserves the right to cancel the program, change dates, how the course is taught, and/or meeting location. If a program is canceled, all program fees will be refunded unless the registered participant elects to transfer to another program. Participants will be notified of any changes within 21 days of the course start date.
Key:
Complete
Next
Failed
Available
Locked